Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP, close the discussion with key takeaways for payers to consider related to ruxolitinib and insights on future research.
Timothy Mok, PharmD, BCPS, BCOP
Advertisement
Articles by Timothy Mok, PharmD, BCPS, BCOP
Gabriela Hobbs, MD, describes characteristics of the patient population included in the MAJIC-PV study, and analyzes best available therapies received in the comparator arm.
Experts on polycythemia vera provide a comprehensive overview of the objectives and study design of the MAJIC-PV clinical trial, highlighting key endpoints.
Advertisement
Latest Updated Articles
Objectives and Study Design of MAJIC-PVPublished: May 8th 2024 | Updated:
Inside MAJIC-PV: A Closer Look at the Patient PopulationPublished: May 8th 2024 | Updated:
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
In America, Aging With HIV is a Continuous Challenge
2
What Health Plans Should Ask For in Their PBM Contracts If They Want Transparency | AMCP Nexus 2025
3
Vaccines in Cancer Care: Evidence, Guidelines & Clinical Considerations
4
Beyond the Primary End Point: Diving Deeper into the EMERALD trial | Written Recap
5
